Epigenetics Drugs Market by Drug Types (ChiP Technology, DNA Methylation), and Mechanism of Action  – DNMT Inhibitors – Azacitidine (Vidaza) and Decitabine (Dacogen); and HDAC Inhibitors or HDIs – Romidepsin (Istodax), Vorinostat (Zolinza) and Forecast 2017-2021

Epigenetics Drugs Market by Drug Types (ChiP Technology, DNA Methylation), and Mechanism of Action  – DNMT Inhibitors – Azacitidine (Vidaza) and Decitabine (Dacogen); and HDAC Inhibitors or HDIs – Romidepsin (Istodax), Vorinostat (Zolinza) and Forecast 2017-2021

Epigenetics regulates gene expression in a reversible manner by chemically modifying DNA and histone proteins, which prevent permanent mutations or alterations within the genes or genome itself. Epigenetics is a study of change in the gene expression without any change in gene sequence. Epigenetic changes beyond a normal expression pattern can cause a variety of diseases. Epigenetic therapy involves use of drugs or other epigenome-influencing techniques to treat medical conditions including cancer, heart disease, diabetes, and mental illnesses. The global epigenetics drugs market growth mainly is driven by factors such as rising incidence of cancer, advancements in screening tools and huge sum invested in research and development activities. The impact of DNMT inhibitors is highly significant for inhibiting the cell cycle growth, and these inhibitors by their mechanism of action account for the major share of the global epigenetics drugs market.

The global epigenetics drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug type (ChIP technology, DNA methylation), and their mechanism of action such as DNMT inhibitors – Azacitidine (vidaza) and Decitabine (dacogen); and HDAC inhibitors or HDIs – Romidepsin (istodax), Vorinostat (zolinza), and forecasts growth trends (CAGR% – 2017 to 2021).

The global epigenetics drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global epigenetics drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global epigenetics drugs market and included in this report are Celgene Corporation, Eisai Pharmaceuticals, Pharmacyclics Inc., Merck & Co Inc. and others.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Epigenetics Drugs Market

1. Drug Type
1.1. Chromatin Immunoprecipitation (ChIP) Technology
1.2. DNA Methylation

2. Mechanism of Action
2.1. DNA Methyltransferase Inhibitors (DNMT Inhibitors)
2.1.1. Azacitidine (Vidaza)
2.1.2. Decitabine (Dacogen)
2.2. Histone Deacetylase Inhibitors (HDAC inhibitors, or HDIs)
2.2.1. Romidepsin (Istodax)
2.2.2. Vorinostat (Zolinza)

3. Company Profiles
3.1. 4SC AG
3.2. Acetylon Pharmaceuticals, Inc.
3.3. Astex Pharmaceuticals Inc.
3.4. Celgene Corporation
3.5. Cellcentric Ltd.
3.6. Celleron Therapeutics Ltd.
3.7. Chroma Therapeutics Ltd.
3.8. Eisai Co. Ltd.
3.9. Envivo Pharmaceuticals Inc.
3.10. Epigentek Group Inc.
3.11. Epizyme, Inc.
3.12. Illumina Inc.
3.13. Mdxhealth
3.14. Merck & Company Inc.
3.15. Novartis International AG
3.16. Oncolys Biopharma Inc.
3.17. Pharmacyclics, Inc.
3.18. Promega Corporation
3.19. Repligen Corporation
3.20. Spectrum Pharmaceuticals
3.21. Syndax Pharmaceuticals, Inc.
3.22. Topotarget A/S
3.23. Valirx plc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*